Showing 1 posts of 1 posts found.
MSD, known as Merck in the US, has announced it is to buy Australian viral immuno-oncology firm Viralytics for $394 …
How will biomarker-led diagnostics reshape respiratory medicine?
Five Facts about COPD
“That gap between innovation and delivery was what stood out to me most”
Agentic commercial: how AI creates dialogue with HCPs and patients to help medicines reach them faster
Fortysomethings’ non-attendance at NHS Health Checks raises concerns, says study